FDA bans another Ranbaxy plant

Share this article:

Ranbaxy's US woes continue. The FDA announced Friday that it has now banned drugs from the firm's Toansa, India, facility. As noted by Bloomberg, this is now the fourth Ranbaxy manufacturing site that's a no-go in terms of providing products to the US. The latest reason: FDA inspectors found workers manipulated testing results so that failed drugs passed testing requirements.

The FDA ban's reach is pretty substantial because it bars fully manufactured drugs from entering the US, in addition to preventing US facilities from incorporating active ingredients from the facility into US-produced items.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.

Study says statins not enough for diabetic hearts

Researchers using an experimental test have discovered that the 50% of surveyed diabetics may also have undetected heart muscle damage.